Corporate ActionJun 9, 2026, 08:23 PM
Parabilis Medicines Prices Upsized IPO of 33.5M Shares at $20, Raising $670M
AI Summary
Parabilis Medicines, Inc. announced the pricing of its upsized initial public offering of 33,500,000 shares of common stock at $20.00 per share, expecting to raise $670 million in gross proceeds. The company also granted underwriters an option to purchase an additional 5,025,000 shares. Concurrently, Parabilis agreed to sell 4,166,666 shares to Regeneron Pharmaceuticals in a private placement at $18.00 per share, anticipating $75 million in proceeds. The common stock is expected to begin trading on the Nasdaq Global Select Market under "PBLS" on June 10, 2026, with both offerings projected to close around June 11, 2026.
Key Highlights
- Parabilis Medicines priced its upsized IPO of 33,500,000 common shares at $20.00 per share.
- The IPO is expected to generate gross proceeds of $670 million, excluding the underwriters' option.
- Underwriters have a 30-day option to purchase an additional 5,025,000 shares.
- A concurrent private placement with Regeneron Pharmaceuticals involves 4,166,666 shares at $18.00 per share.
- The private placement is expected to yield approximately $75 million in proceeds.
- Parabilis common stock is expected to begin trading on Nasdaq Global Select Market on June 10, 2026, under "PBLS".
- Both the IPO and concurrent private placement are expected to close around June 11, 2026.
Price Impact
More from PBLS